Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV autologous bone marrow-derived mesenchymal stem cells for chronic cervical spinal cord injury (AIS C–D)
jRCT2013230003Recruiting
- Sponsor
- Nipro Corporation
- Start
- Mar 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Randomised, double-blind trial of autologous bone marrow derived mesenchymal stromal cells in spinal cord injury (SCI) (2 arms), sponsored by Nipro Corporation. Started Mar 2023; status: recruiting.
02
Drugs
autologous bone marrow derived mesenchymal stromal cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on jRCT2013230003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2013230003.